{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:43:55Z","timestamp":1790934235788,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.vaccine.2009.11.030","type":"journal-article","created":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T21:19:40Z","timestamp":1259356780000},"page":"1209-1216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE\u00ae"],"prefix":"10.1016","volume":"28","author":[{"given":"Alfred","family":"von Krempelhuber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Vollmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Pokorny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Rapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Siersbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Kollaritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.11.030_bib1","unstructured":"Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva, Switzerland: WHO; 1988, www.whqlibdoc.who.int\/smallpox\/9241561106.pdf."},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2009.11.030_bib2","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ijid.2004.09.002","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int J Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2009.11.030_bib3","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM196911272812201","article-title":"Complications of smallpox vaccination, 1968","volume":"281","author":"Lane","year":"1969","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2009.11.030_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jama.1970.03170160031005","article-title":"Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968","volume":"212","author":"Lane","year":"1970","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.vaccine.2009.11.030_bib5","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1001\/jama.289.24.3278","article-title":"US military smallpox vaccination program experience","volume":"289","author":"Grabenstein","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2009.11.030_bib6","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","author":"Kemper","year":"2002","journal-title":"Eff Clin Pract"},{"issue":"7","key":"10.1016\/j.vaccine.2009.11.030_bib7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/aje\/kwh269","article-title":"Myopericarditis following smallpox vaccination","volume":"160","author":"Arness","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2009.11.030_bib8","unstructured":"ACAM2000 Vaccines and Related Biological Products Advisory Committee (VRBPAC) Briefing Document; 2007. April 2007. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4292B2-00-index.htm."},{"issue":"1","key":"10.1016\/j.vaccine.2009.11.030_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Passage history: Abstammung, Eigenschaften und Verwendung des attenuierten Vaccina-Stammes MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2009.11.030_bib10","first-page":"375","article-title":"[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol [B]"},{"issue":"47","key":"10.1016\/j.vaccine.2009.11.030_bib11","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.vaccine.2009.11.030_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified Vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","author":"Suter","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2009.11.030_bib13","first-page":"407","article-title":"IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection","volume":"10","author":"Jones","year":"2008","journal-title":"Curr Opin Mol Ther"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2009.11.030_bib14","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1099\/vir.0.83156-0","article-title":"Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara","volume":"88","author":"Meisinger-Henschel","year":"2007","journal-title":"J Gen Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2009.11.030_bib15","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI33940","article-title":"Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection","volume":"118","author":"Samuelsson","year":"2008","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.vaccine.2009.11.030_bib16","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J Virol"},{"issue":"6979","key":"10.1016\/j.vaccine.2009.11.030_bib17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"issue":"31","key":"10.1016\/j.vaccine.2009.11.030_bib18","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2009.11.030_bib19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1099\/vir.0.80660-0","article-title":"An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model","volume":"86","author":"Law","year":"2005","journal-title":"J Gen Virol"},{"issue":"13","key":"10.1016\/j.vaccine.2009.11.030_bib20","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 10","key":"10.1016\/j.vaccine.2009.11.030_bib21","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1099\/vir.0.82068-0","article-title":"Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara","volume":"87","author":"Staib","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.11.030_bib22","unstructured":"Mateo L, Chaplin P, inventors. Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents. WO 2006\/089690 A1. 2006."},{"issue":"12","key":"10.1016\/j.vaccine.2009.11.030_bib23","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2009.11.030_bib24","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2009.11.030_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine","volume":"8","author":"Kennedy","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2009.11.030_bib26","unstructured":"21 CFR Parts 314 (subpart I) and 601 (subpart H). New drug and biological drug products; Evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible; 2002. Food and Drug Administration, HHS."},{"issue":"9580","key":"10.1016\/j.vaccine.2009.11.030_bib27","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.vaccine.2009.11.030_bib28","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2009.11.030_bib29","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.vaccine.2008.11.079","article-title":"Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax\u00ae in healthy vaccinia-naive adults","volume":"27","author":"Frey","year":"2008","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2009.11.030_bib30","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2003.11.053","article-title":"Smallpox vaccination and myopericarditis: a clinical review","volume":"43","author":"Cassimatis","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.vaccine.2009.11.030_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","article-title":"Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination","volume":"44","author":"Eckart","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.vaccine.2009.11.030_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.amjmed.2008.07.025","article-title":"Electrocardiography screening for cardiotoxicity after modified vaccinia Ankara vaccination","volume":"122","author":"Sano","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.vaccine.2009.11.030_bib33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1128\/JVI.01797-08","article-title":"Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement","volume":"83","author":"Benhnia","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.11.030_bib34","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1128\/JVI.02061-06","article-title":"Induction of natural killer cell responses by ectromelia virus controls infection","volume":"81","author":"Parker","year":"2007","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2009.11.030_bib35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1086\/376557","article-title":"Development of a novel vaccinia-neutralization assay based on reporter-gene expression","volume":"188","author":"Manischewitz","year":"2003","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2009.11.030_bib36","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0731-7085(99)00244-7","article-title":"Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective","volume":"21","author":"Findlay","year":"2000","journal-title":"J Pharm Biomed Anal"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2009.11.030_bib37","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1099\/vir.0.010553-0","article-title":"Evaluation of smallpox vaccines using variola neutralization","volume":"90","author":"Damon","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.11.030_bib38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2009.11.030_bib39","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.vaccine.2009.01.038","article-title":"Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response","volume":"27","author":"Lustig","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09018052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09018052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:16:42Z","timestamp":1759400202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09018052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0264410X09018052"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.11.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE\u00ae","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}